Philanthropy and investors can support crucial psychedelic research and initiatives beyond commercial interests to shape the field and promote equity and social value in the psychedelic economy.
Sandy Samberg
Building better business can drive change, improve social outcomes, and regenerate the environment. Learn from successful individuals who have integrated principles into their company operations for global impact.
David Champion
Vicky Dulai of Compassion For Addiction moderates a discussion with Amy Emerson of MAPS Public Benefit Corporation and Rachel Yehuda of Icahn School of Medicine on leadership in the psychedelic
Rachel Yehuda
Hardman provides a quick overview of the emerging psychedelic sector, covering financial, research, and policy landscapes with data visuals. He also explores unanswered questions about the sector's future.
Josh Hardman
MDMA-assisted therapy (MDMA-AT) shows promise in treating PTSD and comorbid eating disorders. A study found significant reductions in eating disorder symptoms with MDMA-AT compared to placebo in severe PTSD patients.
Adele LaFrance, Timothy Brewerton
Psilocybin therapy tested for safety, feasibility, and efficacy in cancer patients with major depressive disorder, using group treatment in a cancer center setting. Clinical trial details: NCT04593563.
Betsy Jenkins